Research location
Potsdam
Germany, Germany
Advertisement
Research activity in Potsdam
Germany, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Potsdam
8 linked trials · page 1 of 1Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.NCT01996319 · 2014-04-01 · 1 site observation
COMPLETED
Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPDNCT01959516 · 2014-02-01 · 1 site observation
COMPLETED
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPDNCT01834885 · 2013-12-01 · 1 site observation
WITHDRAWN
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)NCT01782326 · 2013-07-01 · 1 site observation
COMPLETED
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01574651 · 2012-05-01 · 1 site observation
COMPLETED
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01490125 · 2011-10-01 · 1 site observation
COMPLETED
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsNCT01120691 · 2010-04-01 · 1 site observation
COMPLETED
Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT)NCT00857012 · 2009-04-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.